RUNDC3A

Across TCGA pan-cancer cohorts, RUNDC3A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RUNDC3A data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RUNDC3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RUNDC3A expression acts as an unfavorable survival marker.

BLCA, OV, and SKCM are the cancer types where RUNDC3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.089	0.720	<.001	30	view →
OV	DFS	Median	All	0.165	0.541	.004	18	view →
SKCM	OS	Median	All	0.092	0.343	.001	7	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RUNDC3A–BLCA (OS)

Open the BLCA breakdown →